Botulinum toxin A versus microwave thermolysis for primary axillary hyperhidrosis: A randomized controlled trial.
JAAD Int
; 15: 91-99, 2024 Jun.
Article
em En
| MEDLINE
| ID: mdl-38495540
ABSTRACT
Background:
Botulinum toxin A (BTX) and microwave thermolysis (MWT) represent 2 treatment modalities for axillary hyperhidrosis with different procedural and efficacy profiles.Objective:
To compare long-term outcomes following BTX vs MWT treatment of axillary hyperhidrosis.Methods:
A prospective, randomized, within-patient, controlled trial, treating axillary hyperhidrosis with contralateral BTX and MWT. Objective sweat measurement and patient-reported outcome measures for sweat and odor were collected at baseline, 6-month and 1-year follow-up (6M/1YFU). Hair reduction and patient treatment preference was also assessed.Results:
Sweat reduction was significant (all P <.01) for both interventions throughout the study. Objectively, sweat reduction was equal at 1-year FU (ΔP =.4282), but greater for BTX than MWT at 6-month FU (ΔP =.0053). Subjective sweat assessment presented comparable efficacy (6MFU ΔP =.4142, 1YFU ΔP =.1025). Odor reduction was significant (all P <.01) following both interventions, whereas only sustaining for MWT (6MFU ΔP =.6826, 1YFU ΔP =.0098). Long-term, hair reduction was visible after MWT, but not BTX (ΔP ≤.0001), and MWT was preferred by the majority of patients (76%).Limitations:
The intrinsic challenges in efficacy assessment.Conclusion:
This study exhibited BTX and MWT with similar sweat reduction, but distinguishable odor and hair reduction at 1-year FU. These findings support individualized treatment approaches for axillary hyperhidrosis based on patient-specific symptoms and preferences.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
JAAD Int
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Dinamarca